+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 102 Pages
  • April 2024
  • GlobalData
  • Novartis AG
  • ID: 1314904
Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. Novartis conducts research in various disease areas through the BioMedical Research division. The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG Key Recent Developments

  • Apr 23, 2024: Novartis Delivers Double-Digit Sales Growth and Core Margin Expansion in Q1, Fy 2024 Guidance Raised
  • Apr 12, 2024: Novartis signs deal for Arvinas’ prostate cancer therapy
  • Mar 15, 2024: Novartis Expands Its Biopharmaceutical Manufacturing Site in Singapore
  • Mar 14, 2024: Biotech's Role in Addressing the Pancreatic Cancer Emergency

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Novartis AG - Key Facts
  • Novartis AG - Key Employees
  • Novartis AG - Key Employee Biographies
  • Novartis AG - Major Products and Services
  • Novartis AG - History
  • Novartis AG - Company Statement
  • Novartis AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Novartis AG - Business Description
  • Geographical Segment: Asia/Africa/Australasia
  • Performance
  • Geographical Segment: Canada and Latin America
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: US
  • Performance
  • R&D Overview
  • Novartis AG - Corporate Strategy
  • Novartis AG - SWOT Analysis
  • SWOT Analysis - Overview
  • Novartis AG - Strengths
  • Novartis AG - Weaknesses
  • Novartis AG - Opportunities
  • Novartis AG - Threats
  • Novartis AG - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Novartis AG, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 23, 2024: Novartis Delivers Double-Digit Sales Growth and Core Margin Expansion in Q1, Fy 2024 Guidance Raised
  • Apr 12, 2024: Novartis signs deal for Arvinas’ prostate cancer therapy
  • Mar 15, 2024: Novartis Expands Its Biopharmaceutical Manufacturing Site in Singapore
  • Mar 14, 2024: Biotech's Role in Addressing the Pancreatic Cancer Emergency
  • Mar 05, 2024: Novartis Shareholders Approve All Resolutions Proposed by the Board of Directors at the Annual General Meeting
  • Jan 31, 2024: Novartis Delivers Strong Full Year Performance, 10% Net Sales and 18% Core Operating Income Growth (Cc¹), With Margin Expansion. Continuing Innovation Momentum With Multiple Positive Ph3 Readouts
  • Jan 31, 2024: Care Access Becomes Newest Member of the National Lipid Association Industry Council, Joining Novartis, Amgen, and Other Cardiovascular Health Leaders
  • Jan 17, 2024: Envision Energy Announces Collaboration with Five Global Healthcare Leaders to Unlock Renewable Energy in Davos
  • Nov 30, 2023: Atropos Health Forms Life Science Advisory Board, Increasing Commitment to Accelerated Drug Development and Clinical Trial Diversity and Inclusion
  • Nov 28, 2023: Novartis Upgrades Mid-Term Sales Growth Guidance, Showcases Its Differentiated Innovative Medicines Strategy and Robust Pipeline at R&D Day
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Novartis AG, Key Facts
  • Novartis AG, Key Employees
  • Novartis AG, Key Employee Biographies
  • Novartis AG, Major Products and Services
  • Novartis AG, History
  • Novartis AG, Subsidiaries
  • Novartis AG, Joint Venture
  • Novartis AG, Key Competitors
  • Novartis AG, Ratios based on current share price
  • Novartis AG, Annual Ratios
  • Novartis AG, Annual Ratios (Cont...1)
  • Novartis AG, Annual Ratios (Cont...2)
  • Novartis AG, Interim Ratios
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Novartis AG, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Novartis AG, Performance Chart (2019 - 2023)
  • Novartis AG, Ratio Charts
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca Plc
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc
  • Pfizer Inc
  • Verona Pharma Plc
  • Novo Nordisk AS
  • GSK plc
  • Takeda Pharmaceutical Co Ltd
  • SELLAS Life Sciences Group Inc
  • Merck & Co Inc
  • Biogen Inc
  • Amgen Inc
  • Sanofi
  • Bristol-Myers Squibb Co
  • Gilead Sciences Inc
  • Eli Lilly and Co
  • SELLAS Life Sciences Group Inc
  • Generex Biotechnology Corp
  • AstraZeneca Plc
  • Acceleron Pharma Inc
  • F. Hoffmann-La Roche Ltd
  • GW Pharmaceuticals Plc
  • GSK plc
  • Johnson & Johnson
  • Flarer SA
  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • Addex Therapeutics Ltd
  • Yumanity Therapeutics Inc
  • Antion Biosciences SA
  • Cassava Sciences Inc
  • Sanofi
  • Eli Lilly and Co
  • Takeda Pharmaceutical Co Ltd
  • Merck & Co Inc
  • Curis Inc
  • Pfizer Inc
  • Verona Pharma Plc
  • Novo Nordisk AS
  • Kuros Biosciences AG